[P4–572]: INTERIM REPORT OF A PHASE 2 PILOT SAFETY AND EFFICACY TRIAL OF GM‐CSF/LEUKINE® IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE. (1st July 2017)